发明名称 Procedimiento modificado de fabricación de IRX-2
摘要 A highly efficient method of making a primary cell derived biologic by purifying mononuclear cells (MNCs) in a automated cell processor to remove contaminating cells by loading leukocytes onto lymphocyte separation medium (LSM) and centrifuging the medium to obtain purified MNCs, storing the MNCs overnight in a closed sterile bag system, stimulating an induction mixture of the MNCs with phytohemagglutinin (PHA) or other mitogen and ciprofloxacin in a scalable cell culture device and producing a primary cell derived biologic from the MNCs, removing the mitogen from the induction mixture by filtering, incubating the induction mixture, clarifying the induction mixture by filtering to obtain a primary cell derived biologic supernatant, and clearing the primary cell derived biologic supernatant from adventitious agents by anion exchange chromatography, filtration. A closed system prevents contamination of the resulting primary cell derived biologic. An automated method of purifying cells. A method of scalably inducing cells.
申请公布号 ES2430389(T9) 申请公布日期 2014.02.06
申请号 ES20090743225T 申请日期 2009.04.14
申请人 IRX THERAPEUTICS, INC. 发明人 FENNINGTON, GEORGE J.;BRANDWEIN, HARVEY J.
分类号 C12P21/04;C12N5/02;C12N13/00 主分类号 C12P21/04
代理机构 代理人
主权项
地址